Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Defining APOBEC-like signature in diffuse large B-cell lymphoma and demonstration of distinct transcriptomic profile. Presenter: Adam Albitar, MD Date: Jun 1, 2026 – – 9 AM – 12PM CDT Abstract: 7075 Poster Board 573 Session Breast Cancer—Metastatic Dominant chromosomal abnormalities in breast cancer
GTC presented abstracts at the 2025 Annual Meeting of the Society for Neuro-Oncology (SNO). GTC participated in the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology (SNO), held at the Hawaii Convention Center in Honolulu, November 19–23, 2025. Our two presented posters are now available for download.
GTC posters at 67th ASH® Annual Meeting (2025) We are delighted to share that GTC collaborated on 12 abstracts at the ASH 2025 Annual Meeting in Orlando, December 6-9. The work represents novel data across machine-learning prediction models, transcriptomic signatures, cell-free RNA (cfRNA) analytics, ethnic-ancestry outcomes, high risk multiple myeloma
Authors: Vanisha Patel1,*, Maciej Kabat1, Andrew Ip2, Sukhdeep Kaur2, Hyung Chan Suh2, Christina Cho2, David Vesole2, Michele Donato2, Maher Albitar2, Scott D. Rowley2 Affiliations:1Hackensack University Medical Center, Hackensack, New Jersey2John Theurer Cancer Center, Hackensack, New Jersey Article history: Received 9 May 2025 | Accepted 11 August 2025 Abstract Allogeneic stem
GTC presented abstracts at ASCO 2025 GTC’s posters from the 2025 Convention of the American Society of Clinical Oncology are now available for download. Please reach out with any questions. Using cell free DNA (cfDNA) and RNA (cfRNA) in the diagnosis and monitoring of primary and metastatic CNS tumors –
GTC Expands Cancer Tests to Europe via Partnership By Yuika Yoshida April 7, 2025 Genomic Testing Cooperative (GTC) is expanding into the European market by partnering with German laboratory Labor Dr. Wisplinghoff. “Our diagnostics tests going out of the U.S. to Europe is democratizing science,” Chief Executive Dr. Maher Albitar told the
Bruce Hough, Maher Albitar Clinical Lymphoma, Myeloma and Leukemia, Vol. 000, No.xxx, 1–3 © 2025 Published by Elsevier Inc. Keywords: CD19 dim, Diffuse large b-cell lymphoma, Relapsed/Refractory, Bispecific T-cell engagers, Third line Introduction Diffuse Large B-cell Lymphoma (DLBCL) is the most common non-Hodgkin’s lymphoma with an estimated 80,620 new case
Aishwarya Sridhar1 · Dylon Patel1 · Alexandra Della Pia2 · Tatyana A. Feldman2,3 · Lori A. Leslie2,3 · Andre H. Goy1,2 · Maher Albitar4 · Andrew Ip2,3Received: 27 June 2024 / Accepted: 19 November 2024© The Author(s) 2024 OPEN AbstractBackground CD19-directed chimeric antigen receptor (CAR) T-cell therapy has revolutionized cancer care for patients with relapsed or refractory (R/R) difuse large B-cell lymphoma (DLBCL). Despite impressive responses seen with CAR
Andrew Ip 1,2,*,† , Maciej Kabat 3,† , Lindsay Fogel 1,4 , Hassan Alkhatatneh 5 , Jason Voss 2, Amolika Gupta 4,6,Alexandra Della Pia 2 , Lori A. Leslie 1,2 , Tatyana Feldman 1,2, Maher Albitar 7 and Andre H. Goy 1,2 1 Department of Oncology, Hackensack Meridian School of
Scott D. Rowley, Maher Albitar, Melissa F. Baker, Alaa Ali, Sukhdeep Kaur, Hyung C. Suh, Andre Goy and Michele L. Donato. Simple Summary: Relapse of disease is a primary cause of treatment failure after allogeneic bone marrow transplantation. Patients may benefit from post-transplant consolidation therapy, but such therapy poses serious
